About Marie Guillou

This author has not yet filled in any details.
So far Marie Guillou has created 146 blog entries.

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic

2021-03-31T12:01:50+02:00

Publication - Epub 2020 Jun 29. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented [...]

Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic2021-03-31T12:01:50+02:00

Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared

2021-03-31T11:52:42+02:00

Publication - Epub 2020 Jul 31. Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared Authors [...]

Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared2021-03-31T11:52:42+02:00

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid

2021-03-31T11:31:02+02:00

Publication - 2020 Oct 17 International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate [...]

International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut-off values for defining mild, moderate and severe types of bullous pemphigoid2021-03-31T11:31:02+02:00

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study

2021-03-31T11:20:45+02:00

Publication - Epub 2020 Sep 16. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study [...]

QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study2021-03-31T11:20:45+02:00

Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire

2021-03-31T11:16:30+02:00

Publication - Epub 2020 Sep 7. Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire [...]

Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire2021-03-31T11:16:30+02:00

De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex Involved in Gene Expression and RNA and Protein Stability, Cause Neurodevelopmental Delay

2021-03-31T11:11:46+02:00

Publication - Epub 2020 Jun 17. De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex Involved in Gene Expression and RNA and [...]

De Novo Variants in CNOT1, a Central Component of the CCR4-NOT Complex Involved in Gene Expression and RNA and Protein Stability, Cause Neurodevelopmental Delay2021-03-31T11:11:46+02:00

Coordinating Center

  • Hôpital Necker Enfants Malades
  • Department of Dermatology
  • 149 rue de Sèvres
  • 75015 Paris

ERN-Skin is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States.
The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit https://ec.europa.eu/health/ern

© Copyright 2012 -    |   ERN Skin  |   All Rights Reserved